ClinicalTrials.gg
CompletedNCT07091942Updated Oct 9, 2026

Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by National Taiwan University Hospital · Observational

How we know · 2 judgments

Updated Oct 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
243
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital — 8 open to participants now, 8 under way, none of them phase 3. Carcinoma, Hepatocellular · National Taiwan University Hospital.

Enrollment
4th of 19
243 · median 150
Started
2025
with 3 others
Observational
19 of 44
3 open now
Registered
42nd of 44
by date

Among the 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital, this one is the 4th largest by enrollment of the 19 observational ones that give a count, is one of 4 that started in 2025, is one of 19 observational ones, and was the 42nd registered.

Carcinoma, Hepatocellular

3,655 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

8 of the 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital, or all of them as a file.
02

Study summary

Combination immunotherapy is currently the standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Approximately 30 % of patients treated with atezolizumab plus bevacizumab (Atezo-Bev) achieve complete or partial tumor response. Some patients who reach a partial response experience enough tumor regression to undergo curative therapies and subsequently attain a disease-free state. However, whether the prognosis of patients who become disease-free after curative therapy equals that of patients who achieve complete response with Atezo-Bev alone is unclear. Likewise, it remains uncertain whether patients who achieve partial response with Atezo-Bev and later undergo curative therapy fare better than those who remain in partial response without further curative treatment. Therefore, we designed this multinational, multicenter, retrospective chart-review study to address these questions.

Planned Cohorts

  • Curative-therapy cohort: Patients with unresectable HCC who achieve partial response to Atezo-Bev and subsequently receive curative therapy-surgical resection, radiofrequency ablation, or definitive radiotherapy-to achieve a disease-free state.
  • Control cohort: Patients with unresectable HCC who achieve complete or partial response to Atezo-Bev but do not undergo subsequent curative therapy.

Methods and End-points Data will be collected from no more than 30 hospitals worldwide, targeting roughly 400 patients in the curative-therapy cohort and 1,200 patients in the control cohort. Medical-record review will gather baseline characteristics, disease status, liver function, Atezo-Bev treatment details, curative-therapy specifics, treatment responses, and survival outcomes. The primary objective is to compare recurrence-free survival between the two cohorts. This retrospective study will close data collection on 31 March 2025.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who obtained CR or PR, according to RECIST version 1.1, after receiving Atezo-Bev as first-line systemic therapy for clinically or histologically diagnosed HCC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologically or clinically (the presence of liver cirrhosis and typical HCC imaging findings by multi-phase CT or MRI) diagnosed HCC.
  2. Received Atezo-Bev containing treatment as systemic therapy for HCC
  3. Patients with or without macrovascular invasion and main portal vein invasion before Atezo-Bev containing treatment can be enrolled
  4. Patients with or without extrahepatic spread before Atezo-Bev containing treatment can be enrolled
  5. Obtained CR or PR, according to version 1.1, to Atezo-Bev treatment

Exclusion criteria

Exclusion Criteria:

  1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
  2. Received anti-CTLA4 antibodies simultaneously with Atezo-Bev Patients who received Atezo-Bev in combination with drugs such as tiragolumab, relatlimab, and tocilizumab were allowed to enter the study.
  3. Received locoregional therapy simultaneously with Atezo-Bev treatment, such as transarterial chemoembolization (TACE), hepatic arterial infusion of chemotherapy (HAIC), transarterial radioembolization, radiofrequency ablation, and microwave ablation before obtaining PR or not for curative intent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
243 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Curative LRT cohort

    Patients who received curative locoregional therapy after obtaining partial response after atezolizumab-bevacizumab treatment

  • Comparative cohort

    Patients who obtained completed or partial response after atezolizumab-bevacizumab treatment and did not receive curative locoregional therapy

This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival

    Time frame: From initiation of atezolizumab-bevacizumab treatment to disease recurrence or date of death from any cause, whichever came first, assessed up to 8 years

07

Study locations

1 site
  • National Taiwan University Hospital
    Taipei, Select 10002, Taiwan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2025 to primary completion in Oct 2026, 14 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2025 → Oct 2026 and completion Jun 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 29, 2025
StartActual
Jul 17, 2025
Primary completionActual
Oct 8, 2026was Dec 2025
CompletionActual
Oct 8, 2026was Jun 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 9, 2026
Primary completion
Dec 31, 2025→Oct 8, 2026 (actual)
Oct 9, 2026
Study completion
Jun 30, 2026→Oct 8, 2026 (actual)
Oct 9, 2026
Enrollment
1600 (estimated)→243 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2025→Oct 8, 2026 (now actual)
    Study completion Jun 30, 2026→Oct 8, 2026 (now actual)
    Enrollment 1600 (estimated)→243 (actual)
    + 2 other changes: site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07091942
Collaborators
Taipei Veterans General Hospital, Taiwan, Chi Mei Medical Hospital, National Taiwan University Hospital Hsin-Chu Branch, National Taiwan University, Taichung Veterans General Hospital, E-DA Hospital, Chiayi Christian Hospital, Srinagarind Hospital, Khon Kaen University
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Jul 17, 2025
Primary completion
Oct 8, 2026
Completion
Oct 8, 2026
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion